Navigation Links
Drug Improves Survival in Mice With Brain Tumors
Date:4/2/2009

Cediranib reduces tissue swelling better than steroids, team says

THURSDAY, April 2 (HealthDay News) -- Anti-angiogenesis drugs reduce edema (swelling of brain tissue) caused by deadly brain tumors called glioblastomas, a new study suggests.

Anti-angiogenesis drugs prevent the formation of new blood vessels that tumors need to grow, the researchers pointed out.

In this study, a Massachusetts General Hospital team found that the experimental anti-angiogenesis drug cediranib reduced edema and improved survival in mice with glioblastomas. The drug inhibits an angiogenesis factor called VEGF, which is abundant in glioblastomas.

"Our findings suggest that anti-angiogenesis therapy can increase patient survival even in the face of persistent tumor growth," study co-senior author Rakesh K. Jain, director of the Steele Laboratory in MGH's radiation oncology department, said in a hospital news release. "In glioblastoma clinical trials, it is important to separate survival analysis from that of tumor response to therapy, since many factors combine to cause patient deaths."

Previous research showed that cediranib temporarily normalized abnormal, leaky blood vessels that had recurred after surgery, radiation or chemotherapy for glioblastoma, reducing edema and the size of tumors. But exactly how the drug did this was unclear. This study clarified that cediranib's beneficial effects resulted from reduction of edema, the study authors said.

"This is the first paper to show that vascular normalization alone, without chemotherapy, can be effective against some tumors by controlling edema, and that this anti-edema effect is better than that of currently used steroids," Jain said.

"Unfortunately, these anti-VEGF agents did not slow the tumor growth rate in these [mouse] models; and since recurrent glioblastomas are highly resistant to currently used chemotherapy drugs, even if vascular normalization increased drug delivery, there may be little or no additional increase in patient survival. We urgently need to find better anti-tumor and anti-angiogenic agents."

The study, which was published online and is expected to be in a future print issue of the Journal of Clinical Oncology, received funding from AstraZeneca Pharmaceuticals, which manufactures cediranib under the brand name Recentin.

More information

The American Brain Tumor Association has more about brain tumors.



-- Robert Preidt



SOURCE: Massachusetts General Hospital, news release, March 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Demonstrates Marteks Algal DHA Oil Improves Blood Triglyceride Lipid Levels
2. Exercise and yoga improves quality of life in women with early-stage breast cancer
3. Enhanced PrecyseCode 2X(TM) Further Accelerates Remote Coding and Improves Cash Flow for Hospitals
4. Weight-based dosing of ribavirin improves outcomes for patients with hepatitis C
5. Kerry Extends, Improves Small Business Innovation Program
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. Grape Consumption Improves Antioxidant Capacity in Humans
8. JCSM: CPAP therapy improves symptoms of depression in OSA patients
9. Early intervention dramatically improves outcomes for new dialysis patients
10. New technique improves purity of medicines
11. Novel medication improves ovarian cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Improves Survival in Mice With Brain Tumors
(Date:12/9/2016)... PA (PRWEB) , ... December 09, 2016 , ... "I ... Fla. "I used this old family recipe, which is meant to relieve gout and ... it gave me a 12-hour energy boost every time. It relieved what VA doctors ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Holy ... in New York, NY, on December 3rd, to benefit Holy Name Medical Center's ... annual event, which raised over $1 million - the largest event in the ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... Fla. , Dec. 9, 2016  Harmar Mobility, LLC announced ... and a member of the Board of Directors. Photo ... ... Mr. Dawson,s ... development of organizations across a variety of industries. He brings to ...
(Date:12/9/2016)... -- Research and Markets has announced the addition of ... offering. ... global travel vaccines market to grow at a CAGR of 6.83% ... scenario and the growth prospects of the global travel vaccines market ... revenue generated from the sales of various vaccines administered to actively ...
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
Breaking Medicine Technology: